TELIX PHARMACEUTICALS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.88 AUD | +4.06% |
|
+18.66% | +47.62% |
| Sales 2024 * | 734M 479M | Sales 2025 * | 911M 594M | Capitalization | 4.92B 3.21B |
|---|---|---|---|---|---|
| Net income 2024 * | 46M 29.99M | Net income 2025 * | 88M 57.37M | EV / Sales 2024 * | 6.52 x |
| Net cash position 2024 * | 129M 84.34M | Net cash position 2025 * | 197M 128M | EV / Sales 2025 * | 5.18 x |
| P/E ratio 2024 * |
104
x | P/E ratio 2025 * |
55
x | Employees | 234 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 76.41% |
More Fundamentals
* Assessed data
More news
Latest transcript on Telix Pharmaceuticals Limited
More press releases
More news
| 1 day | +4.06% | ||
| 1 week | +18.66% | ||
| Current month | +15.44% | ||
| 1 month | +18.19% | ||
| 3 months | +35.03% | ||
| 6 months | +75.68% | ||
| Current year | +47.62% |
1 week
13.46
14.99
1 month
11.8214.99
Current year
9.1314.99
1 year
8.2014.99
3 years
3.5514.99
5 years
0.7614.99
10 years
0.4614.99
| Managers | Title | Age | Since |
|---|---|---|---|
Andreas Kluge
FOU | Founder | - | 15-10-31 |
| Founder | - | 15-10-31 | |
Darren Smith
DFI | Director of Finance/CFO | 58 | 22-01-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Harry McCann
CHM | Chairman | 83 | 17-09-16 |
| Founder | - | 15-10-31 | |
Mark Nelson
BRD | Director/Board Member | - | 17-09-16 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.39% | 16 M€ | -7.62% | ||
| 0.04% | 773 M€ | -.--% | - | |
| 0.01% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 14.88 | +4.06% | 1,735,593 |
| 24-04-23 | 14.3 | +1.42% | 1,508,493 |
| 24-04-22 | 14.1 | +3.60% | 1,052,608 |
| 24-04-19 | 13.61 | -0.80% | 1,407,698 |
| 24-04-18 | 13.72 | +9.41% | 3,146,566 |
Delayed Quote Australian S.E., April 24, 2024 at 02:10 am EDT
More quotes
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company. The Company is focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its core pipeline is focused on prostate cancer, renal cancer, brain cancer (glioma) and rare diseases (hematologic cancers and bone marrow conditioning). Its pipelines include TLX591, TLX592 (alpha-RADmAb), TLX591-CDx, TLX250, TLX250-CDx, TLX101, TLX101-CDx, TLX300, TLX300-CDx, TLX66, and TLX66-CDx. TLX591 is a radio antibody-drug conjugate (rADC) directed at prostate-specific membrane antigen (PSMA). Its product QUANTM Irradiation System (QIS), enables production of important medical isotopes such as gallium-68 (68Ga), zirconium-89 (89Zr), technetium-99m (99mTc) and copper-64 (64Cu).
Calendar
2024-05-21
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
14.88
AUD
Average target price
15.29
AUD
Spread / Average Target
+2.75%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +47.62% | 3.19B | |
| +4.09% | 43.84B | |
| +47.81% | 41.25B | |
| +9.45% | 41.68B | |
| -10.92% | 27.04B | |
| +9.32% | 25.53B | |
| -24.87% | 18.18B | |
| +29.70% | 12.29B | |
| +1.28% | 12.29B | |
| +7.78% | 11.15B |
- Stock Market
- Equities
- TLX Stock
